Mori Shinichiro, Inaniwa Taku, Furukawa Takuji, Takahashi Wataru, Nakajima Mio, Shirai Toshiyuki, Noda Koji, Yasuda Shigeo, Yamamoto Naoyoshi
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan.
J Radiat Res. 2014 Sep;55(5):948-58. doi: 10.1093/jrr/rru032. Epub 2014 May 15.
Amplitude-based gating aids treatment planning in scanned particle therapy because it gives better control of uncertainty with the gate window. We have installed an X-ray fluoroscopic imaging system in our treatment room for clinical use with an amplitude-based gating strategy. We evaluated the effects of this gating under realistic organ motion conditions using 4 DCT data of lung and liver tumors. 4 DCT imaging was done for 24 lung and liver patients using the area-detector CT. We calculated the field-specific target volume (FTV) for the gating window, which was defined for a single respiratory cycle. Prescribed doses of 48 Gy relative biological effectiveness (RBE)/fraction/four fields and 45 Gy RBE/two fractions/two fields were delivered to the FTVs for lung and liver treatments, respectively. Dose distributions were calculated for the repeated first respiratory cycle (= planning dose) and the whole respiratory data (= treatment dose). We applied eight phase-controlled rescannings with the amplitude-based gating. For the lung cases, D95 of the treatment dose (= 96.0 ± 1.0%) was almost the same as that of the planning dose (= 96.6 ± 0.9%). D(max)/D(min) of the treatment dose (= 104.5 ± 2.2%/89.4 ± 2.6%) was slightly increased over that of the planning dose (= 102.1 ± 1.0%/89.8 ± 2.5%) due to hot spots. For the liver cases, D95 of the treatment dose (= 97.6 ± 0.5%) was decreased by ∼ 1% when compared with the planning dose (= 98.5 ± 0.4%). D(max)/D(min) of the treatment dose was degraded by 3.0%/0.4% compared with the planning dose. Average treatment times were extended by 46.5 s and 65.9 s from those of the planning dose for lung and liver cases, respectively. As with regular respiratory patterns, amplitude-based gated multiple phase-controlled rescanning preserves target coverage to a moving target under irregular respiratory patterns.
基于幅度的门控有助于扫描粒子治疗中的治疗计划制定,因为它能更好地控制门控窗口的不确定性。我们在治疗室安装了一台X射线荧光透视成像系统,用于基于幅度门控策略的临床应用。我们使用肺部和肝脏肿瘤的4DCT数据,在实际器官运动条件下评估了这种门控的效果。使用面积探测器CT对24例肺部和肝脏患者进行了4DCT成像。我们计算了门控窗口的特定野靶体积(FTV),该窗口是为单个呼吸周期定义的。分别为肺部和肝脏治疗的FTV给予48 Gy相对生物效应(RBE)/分次/四野和45 Gy RBE/两次分次/两野的处方剂量。计算了重复的第一个呼吸周期(=计划剂量)和整个呼吸数据(=治疗剂量)的剂量分布。我们应用了基于幅度门控的八次相位控制重新扫描。对于肺部病例,治疗剂量的D95(=96.0±1.0%)与计划剂量的D95(=96.6±0.9%)几乎相同。由于热点,治疗剂量的D(max)/D(min)(=104.5±2.2%/89.4±2.6%)比计划剂量的D(max)/D(min)(=102.1±1.0%/89.8±2.5%)略有增加。对于肝脏病例,治疗剂量的D95(=97.6±0.5%)与计划剂量(=98.5±0.4%)相比降低了约1%。与计划剂量相比,治疗剂量的D(max)/D(min)降低了3.0%/0.4%。肺部和肝脏病例的平均治疗时间分别比计划剂量的平均治疗时间延长了46.5秒和65.9秒。与正常呼吸模式一样,基于幅度的门控多相位控制重新扫描可在不规则呼吸模式下保持对移动靶标的靶区覆盖。